Roberto Ferrara

🌓Yin&Yang Masterclass 2025 1st edition comes to an end. Huge thanks to all young and early-career investigators for stepping up, and to the stellar faculty for guiding them with passion and vision. Next stop: Paris 2026 🇨🇵 Stay tuned! #YinYang2025 @mihaela_aldea @BRicciutiMD

🧠Do we know enough about TKI pharmacological principles (Tachyphylaxis, interactions..)?🧪 Don’t miss the @EORTC -PAMM joint webinar! 📅 July 22, 6 PM 🔗 Register now to get access: lnkd.in/eQnG6XDN Let’s close the season with science!☀️🏝️ #EORTClung #LungCancer

📢 Don’t miss next week’s webinar! Join the EORTC Lung Cancer & PAMM Groups on 22 July to explore how pharmacological interactions impact thoracic oncology treatment. 🔗 Register now: eortc.wufoo.com/forms/z1ov02va… #EORTClung #EORTCpamm #OncologyWebinar #Pharmacology #LungCancer

Milano was full of knowledge, fearless debates and mentorship. Thank you to the organizing committee for the invitation @BRicciutiMD @mihaela_aldea and Roberto Ferrara Day #1 workshop with fellows Day #2 Debate

Honored to be part of the Yin&Yang Lung Cancer Masterclass in Milan 🇮🇹 Presented a case on EGFR-mutant NSCLC, had the chance to see a great debate led by @JuliaRotow and @BenjaminBesseMD and connected with young oncologists from around the world.

Brilliant event with dynamic debates, meaningful discussions on how we interpret clinical studies and great conversations with colleagues from all over! Huge thanks to @RobertoFerrara_ @mihaela_aldea and @BRicciutiMD for organising such a fresh and engaging meeting! #YinYang2025

Dynamic debate b/w @JuliaRotow & @BenjaminBesseMD on 1L combos vs 1L osi for #EGFR+ NSCLC 💠#FLAURA2 & #MARIPOSA more effective for most subgroups than osi alone: highly important for pts w/⬆️risk features 💠Significant tox of MARIPOSA: need for mitigation (subQ ami, COCOON ppx)

Honored to participate in a vibrating series of debates in hot topics in lung cancer. Very inspiring for young oncologists and really challenging for the faculty to keep it fair and funny. Great initiative and bold format. Congrats for the success!! 👏 @RobertoFerrara_…

Enjoyed participating in the session on adjuvant #EGFR & #ALK TKI at Yin & Yang Lung Cancer Masterclass w/ @Tony_Calles & @MarianaBrandao0 w/ important debate on role of adjuvant chemo prior to TKI. Thanks to @mihaela_aldea @RobertoFerrara_ @BRicciutiMD for the chance to present!

Fantastic debate b/w @JessicaJLinMD & @NarjustFlorezMD at Yin & Yang Lung Ca Masterclass: 1L lorlatinib vs 1L 2G TKIs for ALK+ mNSCLC 💠Median PFS >5yrs of 1L lorla. More limited 2L+ activity especially w/o secondary mut 💠More challenging tox of lorla: neurocog AE,⬆️wt, HLD, etc

Excited to be at the Yin & Yang Lung Cancer Masterclass organized by @mihaela_aldea @RobertoFerrara_ @BRicciutiMD. Innovative roundtable on clinical trial design + engaging & informative workshop/article discussions. Honored to be in Milan at the 1st Ed of this amazing conference

🔥 A brilliant case by @CMHidalgoFilho in EGFR+ NSCLC ignites one of the hottest debates: MARIPOSA vs FLAURA2 vs FLAURA at #Yin&Yang 2025 conference in Milan 💥 On stage 2 titans @BenjaminBesseMD & @JuliaRotow face off in a thought-provoking showdown @mihaela_aldea @BRicciutiMD

Debating my ALK sister today at the Ying & Yang Lung Cancer Masterclass in Milan, Italy @ALKPositiveinc @ALKpositiveINT @YoungLungCancer

1st Edition Ying & Yang Lung Cancer Masterclass Organized by @mihaela_aldea @BRicciutiMD @RobertoFerrara_ Today - Fellows Workshop Team 4 with Dr. Lin

Great post by @FabioSalomone22 @AntonioNuccio01 @RobertoFerrara_ Nice graph with PR, AR and the complex Immune Features. Despite 10 years of the ICI and the long tails of some trials we have very poor patient selection. #Oncology #LCSM #LungCancer #LungCancerResearch

🧬 Not all curves tell the truth. Network effect fuels hype, not biology. All comers blur the signal. Immunotherapy lives a Barabasian fame amplified, unequal, untested. The Dorian Gray of oncology smiles. But winter has come. doi.org/10.1016/j.jtho… @oncolive #IOtrials #PDL1

💡Starting out in thoracic oncology? The @IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders @JTOonline @OncoAlert #LCSM jto.org/article/S1556-…

⭐️A fantastic, balanced, and comprehensive editorial from @RobertoFerrara_ & colleagues - they do an elegant job dissecting many of my concerns with the state of IO clinical trial development. KEY POINTS: 1️⃣ Not all ICIs are equivalent & bind to varied epitopes. While single…

❄️Winter of cancer immunotherapy is here. 𝐀𝐥𝐥-𝐜𝐨𝐦𝐞𝐫𝐬 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 & 𝐍𝐞𝐭𝐰𝐨𝐫𝐤-𝐞𝐟𝐟𝐞𝐜𝐭 slowed progress-we’ve hit a plateau. Time to prioritize innovation over convention! Editorial out in @JTOonline bit.ly/4eEVcv4 @FabioSalomone22 @AntonioNuccio01

Bravo @BenjaminBesseMD! Very welcome news. Looking forward to your Presidency